<DOC>
	<DOC>NCT01590199</DOC>
	<brief_summary>This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus.</brief_summary>
	<brief_title>Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion and Patients eligible for inclusion in this extension study have to meet all of the additional inclusion criteria: The patient must provide a signed Informed Consent Form (ICF) for the extension study prior to any study related procedures Completion of the whole treatment period of 15 months (3 months monotherapy with either pasireotide LAR or everolimus followed by a 12 months combination of pasireotide LAR/everolimus) in the CSOM230F2102 study No tumor progression during 12 months of combination therapy with pasireotide LAR and everolimus (checked via radiologically assessment). No intolerable toxicity during combination therapy with pasireotide LAR and everolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>